The National Institute for Health and Care Excellence (NICE) approved ipilimumab (anti-CTLA4) for the treatment of metastatic melanoma in 2012 11, followed by pembrolizumab and nivolumab, which target the PD-1 axis. This evidence concerns the gene PDCD1 and metastatic melanoma.